Brokerages Set Encompass Health Co. (NYSE:EHC) PT at $90.29

Encompass Health Co. (NYSE:EHC) has received an average recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $92.00.

Several research analysts have recently weighed in on EHC shares. Barclays upped their target price on Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Raymond James reissued a “strong-buy” rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Royal Bank of Canada increased their price objective on Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, May 22nd. Mizuho increased their price objective on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Truist Financial raised their target price on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Friday, February 9th.

Encompass Health Trading Down 0.1 %

Shares of EHC stock opened at $84.49 on Monday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The company has a market cap of $8.51 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 1.32 and a beta of 0.92. The stock has a 50 day simple moving average of $82.21 and a 200-day simple moving average of $74.07. Encompass Health has a 1-year low of $57.55 and a 1-year high of $87.94.

Encompass Health (NYSE:EHC) last announced its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.19. The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.88 EPS. On average, equities research analysts expect that Encompass Health will post 4.1 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Friday, June 28th. Encompass Health’s dividend payout ratio is presently 16.22%.

Insider Transactions at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 10,000 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the completion of the transaction, the insider now directly owns 18,594 shares in the company, valued at approximately $1,580,861.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Mark J. Tarr sold 44,976 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Elissa Joy Charbonneau sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $85.02, for a total value of $850,200.00. Following the transaction, the insider now owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,519 shares of company stock worth $5,816,091. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Encompass Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Encompass Health by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company’s stock valued at $839,520,000 after acquiring an additional 169,113 shares during the period. Wellington Management Group LLP boosted its holdings in Encompass Health by 5.8% during the 4th quarter. Wellington Management Group LLP now owns 8,215,770 shares of the company’s stock valued at $548,156,000 after acquiring an additional 449,230 shares during the period. William Blair Investment Management LLC raised its position in Encompass Health by 6.4% in the 3rd quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock valued at $381,226,000 after purchasing an additional 342,512 shares in the last quarter. Invesco Ltd. raised its position in Encompass Health by 22.3% in the 3rd quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock valued at $266,914,000 after purchasing an additional 724,544 shares in the last quarter. Finally, TD Asset Management Inc raised its position in Encompass Health by 16.0% in the 1st quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock valued at $188,586,000 after purchasing an additional 314,488 shares in the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.